Metformin Inhibits Inflammation by Targeting the NLRP3 Inflammasome: Linking NF-κB/NEK7/AMPK Signaling to...

Area of Science:

• * Pharmacology
• * Immunology
• * Cellular Biology

Background:

• * Metformin is a primary treatment for type 2 diabetes.
• * It possesses anti-inflammatory properties beyond glucose control.
• * Its role in inhibiting the NOD-like receptor pyrin domain containing 3 (NLRP3) inflammasome is established, but mitochondrial involvement requires further study.

Purpose of the Study:

• * To review how metformin regulates inflammation via multiple pathways.
• * To elucidate the role of mitochondria in metformin's anti-inflammatory effects.
• * To explore metformin's potential in treating inflammasome-driven diseases.

Main Methods:

• * Literature review of studies on metformin, inflammation, and mitochondria.
• * Analysis of metformin's effects on key inflammasome pathways (TLR4/NF-κB, NEK7, AMPK, JAK2-STAT).
• * Examination of metformin's impact on mitochondrial functions related to NLRP3 activation.

Main Results:

• * Metformin regulates inflammation through TLR4/NF-κB, NEK7, AMPK, and JAK2-STAT pathways, involving mitochondria.
• * Metformin's mitochondrial effects inhibit NLRP3 activation steps: NEK7 assembly, reactive oxygen species (ROS) production, thioredoxin-interacting protein (TXNIP) expression, and caspase 1 activity.
• * Metformin reduces IL-1β/IL-18 maturation.

Conclusions:

• * Metformin modulates NLRP3 inflammasome activation through mitochondrial regulation.
• * Metformin shows promise for treating multi-organ diseases associated with inflammasome pathways.
• * Clinical trials are warranted to assess metformin's efficacy in NLRP3 inflammasome-driven pathologies beyond diabetes.